Apollomics (APLM) Current Deferred Tax Assets (2022 - 2023)

Apollomics (APLM) reported Current Deferred Tax Assets of $41.2 million for Q2 2023, down 5.05% quarter-over-quarter from $43.4 million in Q4 2022.

Apollomics (APLM) Current Deferred Tax Assets (2022 - 2023) Analysis & Trends

Apollomics (APLM) has 2 years of Current Deferred Tax Assets data on file, last reported at $41.2 million in Q2 2023.

Current Deferred Tax Assets for Q2 2023 came in at $41.2 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $41.2 million (changed N/A YoY), and the FY2024 annual result was $2.9 million, changed N/A from the prior year.
Current Deferred Tax Assets fell to $41.2 million in Q2 2023 per APLM's latest filing, from $43.4 million in the prior quarter.
Over five years, Current Deferred Tax Assets peaked at $43.4 million in Q4 2022 and troughed at $41.2 million in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	Apollomics	294.00 Mn	294.00 Mn	-

Download Data